Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Les Sulewski
Period: Reporting periods mapped to calendar 2025 Q3 – 2026 Q1 (3 quarters).
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 1 company
VTRSViatris4 questions · 3 reporting periods · 0 of 4 challenging
Calendar 2026 Q1
How much of that was tied to product sales versus onetime channel stocking
Show response
Paul confirmed $71M new product revenue in line with expectations, no channel stocking impact. BD priorities unchanged: in-market accretive assets. Scott confirmed no changes to capital allocation or financial policy with CFO transition.
Calendar 2025 Q4
can you quantify the regulatory pricing challenges you are seeing across the region
Show response
Scott acknowledged structural pricing headwinds from mandatory annual price decreases. Adding EFFEXOR, pitolisant, and spydia to drive Japan from decline to growth by 2028. Doretta noted Amitiza LOE impact mid-year. Cost savings are genuine efficiency gains, not divestiture cleanup.
Calendar 2025 Q3
perhaps maybe give us an update, if you could, on the Indore resolution situation
Show response
Scott confirmed largely remediated, productive FDA meeting on remediation and reinspection. Reinspection likely unannounced in 2026. Built redundancies by qualifying other sites and adding third-party vendors.
one being the uptick in Lipitor, are you able to capture some of the share from the recent generic recall? And then second, what's driving the uptick in EpiPen
Show response
Doretta attributed Lipitor strength to China brand performance. EpiPen share stable at 24-25% with growth from Canada relaunch and strong European performance. Scott reemphasized overall China affiliate strength.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| VTRS Viatris | 4 | 0%none of 4 questions |
- VTRSViatris · 4 questions0%none of 4 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q3 | 2 | 0%none of 2 questions | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
- 2025 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Revenue Growth2
- Competitive Dynamics2
- Product Launch1
- M&A1
- Regulation Policy1